FDA Clearance Tracker · P030040-S008
ADVIA CENTAUR HBC IGM ASSAY
Last checked: Nov 20, 2026Latest source record: Oct 15, 2012 (this decision)Source: openFDAMethods & limitations
Decided
Oct 15, 2012
Approved
Time to decision
203 days
Received Mar 26, 2012. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class II
The decision
- FDA number
- P030040-S008
- Device name
- ADVIA CENTAUR HBC IGM ASSAY
- Applicant
- Siemens Healthcare Diagnostics
- Applicant location
- East Walpole, MA
- Received
- Mar 26, 2012
- Decided
- Oct 15, 2012
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P030040
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.3172
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR A MANUFACTURING SITE LOCATED AT STRATEC BIOMEDICAL SWITZERLAND AG IN BERINGEN, SWITZERLAND.
Source documents
Other decisions for Siemens Healthcare Diagnostics
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K260674 · Decided Nov 6, 2026 · 249 days after receipt
Device type: System, Test, Vitamin D (MRG) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.